Kodiak Sciences Inc
KOD23.040USD
+2.030+9.66%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
1.22B시가총액
손실P/E TTM
자세한 내용은 Kodiak Sciences Inc 회사
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences Inc 정보
종목 코드 KOD
회사 이름Kodiak Sciences Inc
상장일Oct 04, 2018
CEOPerlroth (Victor)
직원 수109
유형Ordinary Share
회계 연도 종료Oct 04
주소1250 Page Mill Rd
도시PALO ALTO
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호94304
전화16502810850
웹사이트https://kodiak.com/
종목 코드 KOD
상장일Oct 04, 2018
CEOPerlroth (Victor)
Kodiak Sciences Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+1152.00%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+1152.00%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: 23 hours ago
마지막 업데이트: 23 hours ago
주주
주주 유형
주주
주주
비율
Baker Bros. Advisors LP
32.66%
Point72 Asset Management, L.P.
4.65%
Perlroth (Victor D)
4.42%
BlackRock Institutional Trust Company, N.A.
3.93%
The Vanguard Group, Inc.
3.79%
기타
50.55%
주주
주주
비율
Baker Bros. Advisors LP
32.66%
Point72 Asset Management, L.P.
4.65%
Perlroth (Victor D)
4.42%
BlackRock Institutional Trust Company, N.A.
3.93%
The Vanguard Group, Inc.
3.79%
기타
50.55%
주주 유형
주주
비율
Hedge Fund
46.25%
Investment Advisor
19.99%
Investment Advisor/Hedge Fund
9.35%
Individual Investor
4.78%
Research Firm
1.78%
Endowment Fund
1.13%
Private Equity
1.04%
Pension Fund
0.17%
Sovereign Wealth Fund
0.08%
기타
15.43%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
262
48.78M
79.97%
+1.55M
2025Q3
248
41.93M
79.39%
-9.11M
2025Q2
273
46.04M
87.25%
-8.67M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Baker Bros. Advisors LP
19.92M
32.66%
+2.61M
+15.07%
Dec 18, 2025
Point72 Asset Management, L.P.
2.84M
4.65%
+2.38M
+526.72%
Sep 30, 2025
Perlroth (Victor D)
2.70M
4.42%
+527.00K
+24.31%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.40M
3.93%
-286.86K
-10.68%
Sep 30, 2025
The Vanguard Group, Inc.
1.95M
3.2%
+127.99K
+7.02%
Sep 30, 2025
Adage Capital Management, L.P.
1.33M
2.19%
-720.71K
-35.06%
Sep 30, 2025
ICONIQ Capital, LLC
1.27M
2.08%
--
--
Sep 30, 2025
TCG Crossover Management, LLC
1.15M
1.88%
--
--
Sep 30, 2025
SilverArc Capital Management, LLC
1.00M
1.64%
+598.46K
+149.04%
Sep 30, 2025
Acadian Asset Management LLC
969.91K
1.59%
-999.97K
-50.76%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Fidelity Enhanced Small Cap ETF
0.18%
iShares Micro-Cap ETF
0.11%
Vanguard US Momentum Factor ETF
0.11%
Invesco RAFI US 1500 Small-Mid ETF
0.06%
iShares Health Innovation Active ETF
0.06%
iShares Russell 2000 Value ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.05%
ProShares Hedge Replication ETF
0.03%
ProShares UltraPro Russell2000
0.03%
Proshares Ultra Russell 2000
0.02%
더 보기
Fidelity Enhanced Small Cap ETF
비율0.18%
iShares Micro-Cap ETF
비율0.11%
Vanguard US Momentum Factor ETF
비율0.11%
Invesco RAFI US 1500 Small-Mid ETF
비율0.06%
iShares Health Innovation Active ETF
비율0.06%
iShares Russell 2000 Value ETF
비율0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
비율0.05%
ProShares Hedge Replication ETF
비율0.03%
ProShares UltraPro Russell2000
비율0.03%
Proshares Ultra Russell 2000
비율0.02%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
